Published in Nature’s sister magazine’Scientific Reports’
(Seoul = Yonhap News) Reporter Gye Seung-hyun = Hanmi Pharmaceutical[128940]On the 13th, it was revealed on the 13th that the results of a cell test showed that the main component of the’Hanmi Cold Mask Nasal Spray’, a respiratory virus blocker applied to the nose, effectively blocks the novel coronavirus infection (Corona 19) virus.
With the support of the Ministry of Science and ICT, the Korea Chemical Research Institute conducted an in vitro cell experiment that evaluated the antiviral activity of lambdacarrageenan, the main component of Korean and American nasal sprays.
The researchers used’EC50′ (50% effective concentration) as an index to evaluate the antiviral activity of lambdacarrageenan against the corona 19-causing virus and influenza virus types A and B, and’SI’, which shows the ratio of cytotoxicity to antiviral activity. (Selectivity index, selectivity index) was used.
The EC50 value indicating antiviral activity in the monkey kidney epithelial-derived fibroblasts (Vero cells) was 0.9±1.1㎍/mL of lambdacarrageenan, and 14.1±0.7㎍/mL of the antiviral drug’remdesivir’, and lambdacarrageenan was 15 times more active. Showed.
In an influenza virus test conducted on dog kidney epithelial-derived cells (MDCK cells), lambdacarrageenan showed antiviral activity equal to or higher than that of previously known chemicals.
In addition, Lambdacarrageenan showed excellent results in SI, which shows safety versus efficacy, explained Hanmi Pharmaceutical. The results of the study were published in Nature’s sister magazine, Scientific Reports.
–
[한미약품 제공. 재판매 및 DB 금지]
–
<저작권자(c) 연합뉴스,
Unauthorized reproduction-redistribution prohibited>
2021/01/13 10:45 sent
–
